Dengue Vaccines Market (Category: Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, and Others; Product: CYD-TDV [Dengvaxia] and Others; Route of Administration: Subcutaneous and Others; and End User: Government Institutes, Specialty Clinics, Hospitals, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2030

Description

Potential Inverse Correlation Between Dengue & COVID-19

Researchers at the Duke University, Oswaldo Cruz Foundation, University of Sao Paulo, and Federal University of Paraiba are stating that immunization with a dengue vaccine could be protective against the COVID-19 infection. It has been found that there were several million cases of dengue fever between January 2019 and July 2020 in Brazil. Those regions where people had high antibody levels for dengue fever had low incidences of coronavirus cases, compounded with a low infection rate and mortality. Such findings are keeping economies running in the dengue vaccines market during the pandemic.

As COVID-19 vaccines have been launched in several countries, vaccine safety communication has become more relevant than ever. Companies in the dengue vaccines market are creating awareness about the dengue vaccine controversy of Philippines in 2016 to facilitate efficient inoculation of COVID-19 and other antiviral vaccines.

Companies Focus on R&D to Develop Licensed Vaccine for All Four Dengue Serotypes

The development of dengue vaccines is potentially challenging, since the virus has antigenically four different serotypes. Companies in the dengue vaccines market are acquiring a strong research base to develop vaccines that are ideal for all four serotypes at the same time. The complex immunopathology of dengue has led to complications in vaccine development.

Dengue vaccines have also been challenged with critical issues such as lack of animal models for the disease and dearth of suitable markers for protective immunity. Several vaccine candidates are in the pipeline for its development with increased emphasis on live attenuated virus vaccines, subunit vaccines, and live chimeric virus vaccines, among others. As such, the Butantan/Merck vaccine is being highly publicized for containing three full-genomes of the four dengue virus serotypes.

Sequential Vaccination Proving More Safe, Effective than Existing Tetravalent Vaccine

In order to improve tetravalent protection, there has been a growing awareness for sequential vaccination in addition to a heterologous prime-boost approach. Companies in the dengue vaccines market are expected to collaborate with researchers such as at the Singapore-MIT Alliance for Research and Technology (SMART), who are capitalizing on the opportunity to make sequential vaccination more safe and effective than the existing tetravalent vaccine. Due to absence of research in animal models, companies are anticipated to find practical ways to induce strong and broad immunity to the dengue virus based on proof-of-concept studies in mice.

The dengue vaccines market is estimated to advance at a robust CAGR of 11% during the forecast period. Companies are increasing their research on the basis of Dengvaxia, which consists of four variant dengue antigens.

Incremental Opportunities in Asia Pacific Encourage Regulatory Submissions for Dengue Vaccine Candidates

The dengue vaccines market is projected to cross US$ 1.4 Bn by 2031. Takeda - a Japan-based multinational pharmaceutical company has begun its regulatory submissions for dengue vaccine candidate, TAK-003, in the EU (European Union) and dengue-endemic countries including Brazil, Indonesia, and Mexico. Other competitor companies are taking cues from such developments and increasing efforts to conduct parallel assessment of medicinal products to innovate in vaccines.

Companies in the dengue vaccines market are increasing the focus on the development of vaccines that can act in the prevention of dengue in individual ages from four to 60 years. They are unlocking growth opportunities in Malaysia, Thailand, and Singapore, among other countries. This is evident since Asia Pacific is expected to dominate the highest revenue share among all regions in the market during the assessment period.

R&D Becomes Deciding Factor for Greater Acceptability of Dengue Vaccines

The commitment to R&D for vaccine development is emerging as one of the most crucial strategies to gain a competitive edge in the dengue vaccines market. Continuous research holds promising potentials for the development of next-gen dengue, malaria, and tuberculosis vaccines. The R&D has become the need of the hour, since greater acceptability, improved production, and cost effectiveness of dengue vaccines are key deciding factors for its success in the market landscape.

The Developing Countries Vaccine Manufacturers Network (DCVMN) is gaining popularity for its growing capacity and willingness to effectively advance vaccine clinical development. Network members linked with the dengue vaccines market are boosting their production capacities to combat high incidence of dengue and other regional infectious diseases in patients.

Access to Safe, Effective Dengue Vaccine Candidates Benefits Endemic Countries

According to the World Health Organization (WHO), dengue represents one of the 10 biggest global health threats. Panacea Biotec - a global generic and specialty pharmaceutical and vaccine maker registered in India has announced the successful completion of phase I/II study of its novel tetravalent recombinant chimeric dengue candidate vaccine DengiAll. Companies in the dengue vaccines market are taking cues from such news, and making efforts to increase access to safe and effective dengue vaccine candidates to minimize the devastating impact of dengue fever in endemic countries such as Colombia, Sri Lanka, and Argentina.

Companies in the dengue vaccines market are innovating in vaccine candidates that induce robust, balanced, and neutralizing antibody response against all four dengue virus serotypes.

Funding Programs Encourage Indo-U.S. Dengue Vaccine Development

The Department of Biotechnology in India is being highly publicized for making concerted efforts to strengthen vaccine R&D through their Vaccine Action Program. Companies in the India dengue vaccines market are taking advantage of this opportunity to participate in the Human Immunology Project Consortium (HIPC) Collaboration, which is a funding program to promote India-U.S. collaborative R&D on human immunophenotyping in the context of infectious diseases and vaccine development.

India’s market for dengue vaccines is undergoing a critical change with the help of National Expert Groups and Indo-U.S. Vaccine Action Program. Stakeholders are gaining awareness about such collaborative initiatives, which are helping to take major strides toward vaccine development for diseases including malaria and dengue. The International Centre for Genetic Engineering and Biotechnology (ICGEB) involving drug major Sun Pharma is using recombinant EDIII- based sub-unit dengue vaccine candidate to develop injectable vaccines.

Analysts’ Viewpoint

Prior immunization with dengue vaccine holds promising potentials to increase antibodies in individuals and prevent the contraction of the coronavirus infection. Although some vaccine candidates are transitioning from animal trials to phase II and III in humans, several issues regarding dengue vaccine implementation in countries such as India need to be addressed. Thus, companies in the India and global dengue vaccines market should capitalize on collaborative efforts made by regulatory bodies, including the WHO, with policy makers in order to standardize field trials for safe and efficacious dengue vaccines. The Indo-U.S. Vaccine Action Program is gaining increased popularity for improvising the current understanding of vaccine science.

Dengue Vaccines Market: Overview

Dengue is a mosquito-borne disease that has majorly affected the tropical and subtropical regions of the world. The disease is caused by four closely resembled deadly viruses (DEN 1, DEN 2, DEN 3, and DEN 4). Like other viral diseases, there is no treatment for dengue fever, but it could be treated if attended in time. Scientists have still not been able to develop a proper vaccine for dengue, as the virus is highly complicated to cure.

Some of the symptoms of dengue include bleeding, bone pain, severe nausea, headaches, rashes, and even death. The virus could last for up to 10 days in human body and leads to loss of life if not assisted medically. Nearly 390 million people are infected by dengue each year in 120 countries, especially in Latin America, Southeast Asia, and Africa. Hence, in order to cure dengue, a proper vaccine would play a vital role in control of the disease.

Dengue vaccines are used to prevent dengue fever in humans. Dengue vaccine is only recommended in patients who had a history of dengue fever. It is delivered as three injections over a year.

Increase in cases of dengue is projected to fuel the growth of the global dengue vaccines market during the forecast period. According to the Pan American Health Organization, around 1,191,815 cases of dengue were reported, of which 546,589 were laboratory-confirmed and 5,599 were segregated as severe dengue in the Americas between the epidemiological week 1 and 22 of 2019.

In 2019, The Western Pacific region reported over 375,000 suspected cases of which, the Philippines reported 176,411 and Malaysia reported 100,028. Rise in prevalence of dengue has driven demand for vaccines, which is anticipated to augment the dengue vaccines market in the near future.

Moreover, R&D on live attenuated vaccines is expected to boost the global market. For instance, in May 2019, the U.S. FDA approved Dengvaxia for the prevention of dengue caused by all types of dengue virus serotypes. Dengvaxia is a live attenuated tetravalent chimeric vaccine made using the recombinant DNA technology.

Market Segmentation: Dengue Vaccines Market

In terms of category, the global dengue vaccines market has been divided into live attenuated vaccines, chimeric live attenuated vaccines, and others. The live attenuated vaccines segment is expected to dominate the global dengue vaccines market during the forecast period, due to increase in awareness about vaccination, surge in government funding for vaccination programs, and rise in prevalence of infectious diseases.

Based on product, the global dengue vaccines market has been bifurcated into CYD-TDV (Dengvaxia) and others. The CYD-TDV (Dengvaxia) segment dominated the global dengue vaccines market in 2020, as the vaccine was determined to be around 76% effective in preventing symptomatic, laboratory-confirmed dengue in individuals nine through 16 years of age who previously had laboratory-confirmed dengue disease.

In terms of route of administration, the global dengue vaccines market has been classified into subcutaneous and others. The subcutaneous segment dominated the global dengue vaccines market in 2020. Advantages of subcutaneous injection are that the vaccine can be administered to patients, as no trained personnel is required and adsorption, even though slow, is usually complete.

Based on end user, the global dengue vaccines market has been categorized into hospitals, government institutes, specialty clinics, and others. Growth of the hospitals segment can be attributed to quick and high-quality services at competitive pricing at these healthcare settings.

Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The dengue vaccines market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2030, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Dengue Vaccines Market

In terms of region, the global dengue vaccines market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 2031, with their CAGRs from 2021 to 2031

The study also offers a list of recommendations, highlights, and useful insights of the global dengue vaccines market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Dengue Vaccines Market Players

The dengue vaccines market report concludes with the company profiles section, which includes key information about major players in the global dengue vaccines market

Leading players analyzed in the report include

  • Sanofi Pasteur Limited
  • Takeda Pharmaceutical Company Limited
  • Merck Co. & Inc.
  • GlaxoSmithKline plc
  • GeneOne Life Science
  • Medigen Vaccine Biologics
  • Panacea Biotec Limited
  • Sun Pharmaceutical Industries Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Biological E, and VabioTech

Each of these players has been profiled in the dengue vaccines market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Key Questions Answered in Dengue Vaccines Market Report

  • What is the sales/revenue generated by dengue vaccines across all regions during the forecast period?
  • What are the opportunities in the global dengue vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which category is expected to generate the highest revenue globally in 2031? Which product is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Dengue Vaccines Market – Segmentation

Category

  • Live Attenuated Vaccines
  • Chimeric Live Attenuated Vaccines
  • Others

Product

  • CYD-TDV (Dengvaxia)
  • Others

Route of Administration

  • Subcutaneous
  • Others

End User

  • Hospitals
  • Government Institutes
  • Specialty Clinics
  • Others

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dengue Vaccines Market

4. Market Overview

    4.1. Introduction

        4.1.1. Category Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Dengue Vaccines Market Analysis and Forecast, 2017–2030

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Disease Prevalence

    5.3. Patient Volume

    5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Dengue Vaccines Market Analysis and Forecast, by Category

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Category, 2017–2030

        6.3.1. Live Attenuated Vaccines

        6.3.2. Chimeric Live Attenuated Vaccines

        6.3.3. Others

    6.4. Market Attractiveness Analysis, by Category 

7. Global Dengue Vaccines Market Analysis and Forecasts, by Product 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Product, 2017–2030

        7.3.1. CYD-TDV (Dengvaxia)

        7.3.2. Others

    7.4. Market Attractiveness Analysis, by Product 

8. Global Dengue Vaccines Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Route of Administration, 2017–2030

        8.3.1. Subcutaneous

        8.3.2. Others

    8.4. Market Attractiveness Analysis, by Route of Administration 

9. Global Dengue Vaccines Market Analysis and Forecast, by End-user 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by End-user, 2017–2030

        9.3.1. Hospitals

        9.3.2. Government Institutes

        9.3.3. Specialty Clinics

        9.3.4. Others

    9.4. Market Attractiveness Analysis, by End-user 

10. Global Dengue Vaccines Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast By Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Market Attractiveness Analysis, by Country/Region

11. North America Global Dengue Vaccines Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Category, 2017–2030

        11.2.1. Live Attenuated Vaccines

        11.2.2. Chimeric Live Attenuated Vaccines

        11.2.3. Others

    11.3. Market Value Forecast, by Product, 2017–2030

        11.3.1. CYD-TDV (Dengvaxia)

        11.3.2. Others

    11.4. Market Value Forecast, by Route of Administration, 2017–2030

        11.4.1. Subcutaneous

        11.4.2. Others

    11.5. Market Value Forecast, by End-user, 2017–2030

        11.5.1. Hospitals

        11.5.2. Government Institutes

        11.5.3. Specialty Clinics

        11.5.4. Others

    11.6. Market Value Forecast, by Country, 2017–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Category 

        11.7.2. By Product 

        11.7.3. By Route of Administration 

        11.7.4. By End-user 

        11.7.5. By Country

12. Europe Global Dengue Vaccines Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Category, 2017–2030

        12.2.1. Live Attenuated Vaccines

        12.2.2. Chimeric Live Attenuated Vaccines

        12.2.3. Others

    12.3. Market Value Forecast, by Product, 2017–2030

        12.3.1. CYD-TDV (Dengvaxia)

        12.3.2. Others

    12.4. Market Value Forecast, by Route of Administration, 2017–2030

        12.4.1. Subcutaneous

        12.4.2. Others

    12.5. Market Value Forecast, by End-user, 2017–2030

        12.5.1. Hospitals

        12.5.2. Government Institutes

        12.5.3. Specialty Clinics

        12.5.4. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Category 

        12.7.2. By Product 

        12.7.3. By Route of Administration 

        12.7.4. By End-user 

        12.7.5. By Country/Sub-region

13. Asia Pacific Global Dengue Vaccines Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Category, 2017–2030

        13.2.1. Live Attenuated Vaccines

        13.2.2. Chimeric Live Attenuated Vaccines

        13.2.3. Others

    13.3. Market Value Forecast, by Product, 2017–2030

        13.3.1. CYD-TDV (Dengvaxia)

        13.3.2. Others

    13.4. Market Value Forecast, by Route of Administration, 2017–2030

        13.4.1. Subcutaneous

        13.4.2. Others

    13.5. Market Value Forecast, by End-user, 2017–2030

        13.5.1. Hospitals

        13.5.2. Government Institutes

        13.5.3. Specialty Clinics

        13.5.4. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2030

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis 

        13.7.1. By Category 

        13.7.2. By Product 

        13.7.3. By Route of Administration 

        13.7.4. By End-user 

        13.7.5. By Country/Sub-region

14. Latin America Global Dengue Vaccines Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Category, 2017–2030

        14.2.1. Live Attenuated Vaccines

        14.2.2. Chimeric Live Attenuated Vaccines

        14.2.3. Others

    14.3. Market Value Forecast, by Product, 2017–2030

        14.3.1. CYD-TDV (Dengvaxia)

        14.3.2. Others

    14.4. Market Value Forecast, by Route of Administration, 2017–2030

        14.4.1. Subcutaneous

        14.4.2. Others

    14.5. Market Value Forecast, by End-user, 2017–2030

        14.5.1. Hospitals

        14.5.2. Government Institutes

        14.5.3. Specialty Clinics

        14.5.4. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2030

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Category 

        14.7.2. By Product 

        14.7.3. By Route of Administration 

        14.7.4. By End-user 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Global Dengue Vaccines Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Category, 2017–2030

        15.2.1. Live Attenuated Vaccines

        15.2.2. Chimeric Live Attenuated Vaccines

        15.2.3. Others

    15.3. Market Value Forecast, by Product, 2017–2030

        15.3.1. CYD-TDV (Dengvaxia)

        15.3.2. Others

    15.4. Market Value Forecast, by Route of Administration, 2017–2030

        15.4.1. Subcutaneous

        15.4.2. Others

    15.5. Market Value Forecast, by End-user, 2017–2030

        15.5.1. Hospitals

        15.5.2. Government Institutes

        15.5.3. Specialty Clinics

        15.5.4. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2030

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Category 

        15.7.2. By Product 

        15.7.3. By Route of Administration 

        15.7.4. By End-user 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Share Analysis, by Company, 2020

    16.2. Company Profiles

        16.2.1. Sanofi Pasteur Limited

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Product Portfolio

            16.2.1.3. SWOT Analysis

            16.2.1.4. Strategic Overview

        16.2.2. Takeda Pharmaceutical Company Limited

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Product Portfolio

            16.2.2.3. SWOT Analysis

            16.2.2.4. Strategic Overview

        16.2.3. Merck Co. & Inc.

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Product Portfolio

            16.2.3.3. SWOT Analysis

            16.2.3.4. Strategic Overview

        16.2.4. GlaxoSmithKline plc

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Product Portfolio

            16.2.4.3. SWOT Analysis

            16.2.4.4. Strategic Overview

        16.2.5. GeneOne Life Science

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Product Portfolio

            16.2.5.3. SWOT Analysis

            16.2.5.4. Strategic Overview

        16.2.6. Medigen Vaccine Biologics

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Product Portfolio

            16.2.6.3. SWOT Analysis

            16.2.6.4. Strategic Overview

        16.2.7. Panacea Biotec Limited

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Product Portfolio

            16.2.7.3. SWOT Analysis

            16.2.7.4. Strategic Overview

        16.2.8. Sun Pharmaceutical Industries Ltd.

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Product Portfolio

            16.2.8.3. SWOT Analysis

            16.2.8.4. Strategic Overview

        16.2.9. Serum Institute of India Pvt. Ltd.

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Product Portfolio

            16.2.9.3. SWOT Analysis

            16.2.9.4. Strategic Overview

        16.2.10. Biological E

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Product Portfolio

            16.2.10.3. SWOT Analysis

            16.2.10.4. Strategic Overview

        16.2.11. VabioTech

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Product Portfolio

            16.2.11.3. SWOT Analysis

            16.2.11.4. Strategic Overview

Choose License Type

Checkout Inquiry Sample